Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
CXCL10
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHORIOGONADOTROPIN ALFA | ? unclear | Mechanistic | DGIdb | |
| TESTOSTERONE | ? unclear | Mechanistic | DGIdb | |
| ATROPINE | ? unclear | Mechanistic | DGIdb | |
| METHYLPREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| ELDELUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| OXALIPLATIN | ? unclear | Mechanistic | DGIdb | |
| GM-CSF | ? unclear | Mechanistic | DGIdb | |
| RITONAVIR | ? unclear | Mechanistic | DGIdb | |
| ZIDOVUDINE | ? unclear | Mechanistic | DGIdb | |
| ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| STAVUDINE | ? unclear | Mechanistic | DGIdb | |
| NI-0801 | ↓ inhibits | Mechanistic | DGIdb | |
| IROPLACT | ? unclear | Mechanistic | DGIdb | |
| CHEMBL5081237 | ↓ inhibits | Mechanistic | 19540.0 nM (Kd) | ChEMBL |
CXCR3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CCL11 | ↓ inhibits | Mechanistic | DGIdb | |
| HYPOGLAUCIN A | ↓ inhibits | Mechanistic | DGIdb | |
| CCL7 | ↓ inhibits | Mechanistic | DGIdb | |
| KALLSTROEMIN D | ↓ inhibits | Mechanistic | DGIdb | |
| CXCL10 | ↑ activates | Mechanistic | DGIdb | |
| DURAMYCIN | ↓ inhibits | Mechanistic | DGIdb | |
| CXCL12Α | ↑ activates | Mechanistic | DGIdb | |
| ACT-777991 | ↓ inhibits | Mechanistic | DGIdb | |
| CCL5 | ↑ activates | Mechanistic | DGIdb | |
| CCL13 | ↑ activates | Mechanistic | DGIdb | |
| CCL19 | ↑ activates | Mechanistic | DGIdb | |
| AMG487 | ↓ inhibits | Mechanistic | DGIdb | |
| [125I]CXCL11 (HUMAN) | ↑ activates | Mechanistic | DGIdb | |
| NBI-74330 | ↓ inhibits | Mechanistic | DGIdb | |
| ACT-660602 | ↓ inhibits | Mechanistic | DGIdb | |
| CXCL11 | ↑ activates | Mechanistic | DGIdb | |
| CCL20 | ↑ activates | Mechanistic | DGIdb | |
| [125I]CXCL10 (HUMAN) | ↑ activates | Mechanistic | DGIdb | |
| CXCL9 | ↑ activates | Mechanistic | DGIdb | |
| DIOSCIN | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL196248 | ↓ inhibits | Mechanistic | 15000.0 nM (IC50) | ChEMBL |
| CHEMBL383346 | ↓ inhibits | Mechanistic | 3300.0 nM (IC50) | ChEMBL |
| CHEMBL194494 | ↓ inhibits | Mechanistic | 3200.0 nM (IC50) | ChEMBL |
| CHEMBL196885 | ↓ inhibits | Mechanistic | 930.0 nM (IC50) | ChEMBL |
| CHEMBL193448 | ↓ inhibits | Mechanistic | 3100.0 nM (IC50) | ChEMBL |
| CHEMBL370482 | ↓ inhibits | Mechanistic | 10000.0 nM (IC50) | ChEMBL |
| CHEMBL197368 | ↓ inhibits | Mechanistic | 5800.0 nM (IC50) | ChEMBL |
| CHEMBL197818 | ↓ inhibits | Mechanistic | 70.0 nM (IC50) | ChEMBL |
| CHEMBL370167 | ↓ inhibits | Mechanistic | 13000.0 nM (IC50) | ChEMBL |
| CHEMBL200891 | ↓ inhibits | Mechanistic | 9800.0 nM (IC50) | ChEMBL |
| CHEMBL382000 | ↓ inhibits | Mechanistic | 890.0 nM (IC50) | ChEMBL |
| CHEMBL372403 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL382938 | ↓ inhibits | Mechanistic | 50.0 nM (IC50) | ChEMBL |
| CHEMBL199406 | ↓ inhibits | Mechanistic | 60.0 nM (IC50) | ChEMBL |
| CHEMBL199301 | ↓ inhibits | Mechanistic | 60.0 nM (IC50) | ChEMBL |
| CHEMBL373008 | ↓ inhibits | Mechanistic | 2150.0 nM (IC50) | ChEMBL |
| CHEMBL371298 | ↓ inhibits | Mechanistic | 2160.0 nM (IC50) | ChEMBL |
| CHEMBL372528 | ↓ inhibits | Mechanistic | 250.0 nM (IC50) | ChEMBL |
| CHEMBL199408 | ↓ inhibits | Mechanistic | 1250.0 nM (IC50) | ChEMBL |
| CHEMBL382502 | ↓ inhibits | Mechanistic | 420.0 nM (IC50) | ChEMBL |
Showing top 40 of 190 agents ranked by evidence tier.
IFNG
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| GANCICLOVIR | ? unclear | Mechanistic | DGIdb | |
| EMAPALUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| TRETINOIN | ? unclear | Mechanistic | DGIdb | |
| AMITRIPTYLINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MELPHALAN | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| EDRECOLOMAB | ? unclear | Mechanistic | DGIdb | |
| METHYLPREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| DOXIFLURIDINE | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| URSODIOL | ? unclear | Mechanistic | DGIdb | |
| PREDNISONE | ? unclear | Mechanistic | DGIdb | |
| BLEOMYCIN | ? unclear | Mechanistic | DGIdb | |
| AMIKACIN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| FONTOLIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| AMG-811 | ↓ inhibits | Mechanistic | DGIdb | |
| THEOPHYLLINE | ? unclear | Mechanistic | DGIdb | |
| PENICILLIN G POTASSIUM | ? unclear | Mechanistic | DGIdb | |
| TRASTUZUMAB | ? unclear | Mechanistic | DGIdb | |
| FUMARIC ACID | ? unclear | Mechanistic | DGIdb | |
| SURAMIN | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN, SODIUM SALT | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC MELATONIN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC AUTOLOGOUS LYMPHOCYTES | ? unclear | Mechanistic | DGIdb | |
| THROMBIN ALFA | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERLEUKIN-1-BETA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL3288259 | ↓ inhibits | Mechanistic | 10000.0 nM (Kd) | ChEMBL |
| CHEMBL3288260 | ↓ inhibits | Mechanistic | 7000.0 nM (Kd) | ChEMBL |
IL15
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| IMMUNOADJUVANT | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT CD40-LIGAND | ? unclear | Mechanistic | DGIdb | |
| BACILLUS CALMETTE-GUERIN ANTIGEN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| ORDESEKIMAB | ? unclear | Mechanistic | DGIdb | |
| MEGESTROL ACETATE | ? unclear | Mechanistic | DGIdb | |
| MYCOPHENOLATE MOFETIL | ? unclear | Mechanistic | DGIdb | |
| TETRADECANOYLPHORBOL ACETATE | ? unclear | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| SIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| LYMPHOKINE-ACTIVATED KILLER CELLS | ? unclear | Mechanistic | DGIdb | |
| CHEMBL4102828 | ↓ inhibits | Mechanistic | 48400.0 nM (Kd) | ChEMBL |
| CHEMBL4103753 | ↓ inhibits | Mechanistic | 19100.0 nM (Kd) | ChEMBL |
| CHEMBL4085144 | ↓ inhibits | Mechanistic | 11600.0 nM (Kd) | ChEMBL |
| CHEMBL4101575 | ↓ inhibits | Mechanistic | 24100.0 nM (Kd) | ChEMBL |
| CHEMBL4066271 | ↓ inhibits | Mechanistic | 19600.0 nM (Kd) | ChEMBL |
| CHEMBL4093847 | ↓ inhibits | Mechanistic | 21200.0 nM (Kd) | ChEMBL |
| CHEMBL4087773 | ↓ inhibits | Mechanistic | 42400.0 nM (Kd) | ChEMBL |
| CHEMBL4088685 | ↓ inhibits | Mechanistic | 26000.0 nM (Kd) | ChEMBL |
| CHEMBL4096400 | ↓ inhibits | Mechanistic | 19000.0 nM (Kd) | ChEMBL |
| CHEMBL4069144 | ↓ inhibits | Mechanistic | 20900.0 nM (Kd) | ChEMBL |
| CHEMBL4070160 | ↓ inhibits | Mechanistic | 25000.0 nM (Kd) | ChEMBL |
| CHEMBL4101389 | ↓ inhibits | Mechanistic | 21800.0 nM (Kd) | ChEMBL |
| CHEMBL4066088 | ↓ inhibits | Mechanistic | 78000.0 nM (Kd) | ChEMBL |
| CHEMBL4067098 | ↓ inhibits | Mechanistic | 16000.0 nM (Kd) | ChEMBL |
| CHEMBL4864820 | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | ChEMBL |
| CHEMBL4878149 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4848978 | ↓ inhibits | Mechanistic | 20000.0 nM (IC50) | ChEMBL |
| CHEMBL4875914 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4868024 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4851186 | ↓ inhibits | Mechanistic | 710.0 nM (IC50) | ChEMBL |
| CHEMBL4846844 | ↓ inhibits | Mechanistic | 280.0 nM (IC50) | ChEMBL |
| CHEMBL4864898 | ↓ inhibits | Mechanistic | 9500.0 nM (IC50) | ChEMBL |
| CHEMBL4847472 | ↓ inhibits | Mechanistic | 14900.0 nM (IC50) | ChEMBL |
| CHEMBL4861648 | ↓ inhibits | Mechanistic | 20000.0 nM (IC50) | ChEMBL |
| CHEMBL4857666 | ↓ inhibits | Mechanistic | 50.0 nM (IC50) | ChEMBL |
| CHEMBL4852416 | ↓ inhibits | Mechanistic | 3900.0 nM (Kd) | ChEMBL |
IL2RB
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| BEMPEGALDESLEUKIN | ? unclear | Mechanistic | DGIdb | |
| DENILEUKIN DIFTITOX | ~ modulates | Mechanistic | DGIdb | |
| MIK-BETA-1 | ↓ inhibits | Mechanistic | DGIdb | |
| BASILIXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ALDESLEUKIN | ? unclear | Mechanistic | DGIdb | |
| HUMIK-BETA-1 | ↓ inhibits | Mechanistic | DGIdb | |
| RECOMBINANT HUMAN INTERLEUKIN-15 | ↑ activates | Mechanistic | DGIdb | |
| DACLIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LEUKOCYTE INTERLEUKIN | ? unclear | Mechanistic | DGIdb | |
| HUMAN INTERLEUKIN-2 | ? unclear | Mechanistic | DGIdb | |
| SIMLUKAFUSP ALFA | ~ modulates | Mechanistic | DGIdb | |
| RECOMBINANT INTERLEUKIN-2 | ? unclear | Mechanistic | DGIdb | |
| PEGENZILEUKIN | ↑ activates | Mechanistic | DGIdb | |
| NOGAPENDEKIN ALFA INBAKICEPT | ↑ activates | Mechanistic | DGIdb |
JAK1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TRICETAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| NEZULCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| IVARMACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| OCLACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| MOMELOTINIB | ↓ inhibits | Mechanistic | 11.0 nM (IC50) | DGIdb |
| DECERNOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GOLIDOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| UPADACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| LEPZACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| BREPOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 30 [PMID: 37057760] | ↓ inhibits | Mechanistic | DGIdb | |
| WXFL10203614 | ↓ inhibits | Mechanistic | DGIdb | |
| LIRUCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| VEXICITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| ILGINATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 5E [PMID: 28580438] | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 25AP [PMID: 37796543] | ↓ inhibits | Mechanistic | DGIdb | |
| ZEMPROCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| PEMBROLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| AZD1480 | ↓ inhibits | Mechanistic | DGIdb | |
| CERDULATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| LONDAMOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| JAK INHIBITOR 20A | ↓ inhibits | Mechanistic | DGIdb | |
| FILGOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GUSACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 8L [PMID: 36053746] | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 13AC [PMID: 33256400] | ↓ inhibits | Mechanistic | DGIdb | |
| FEDRATINIB | ↓ inhibits | Mechanistic | 100.0 nM (IC50) | DGIdb |
| FILGOTINIB MALEATE | ↓ inhibits | Mechanistic | DGIdb | |
| PF-956980 | ↓ inhibits | Mechanistic | DGIdb | |
| SDC-1801 | ↓ inhibits | Mechanistic | DGIdb | |
| ROPSACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 18E [PMID: 31670517] | ↓ inhibits | Mechanistic | DGIdb | |
| UPADACITINIB HEMIHYDRATE | ↓ inhibits | Mechanistic | DGIdb | |
| BLOVACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| DEURUXOLITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| RUXOLITINIB PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| SOLCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| CEE321 | ↓ inhibits | Mechanistic | DGIdb | |
| NIK INHIBITOR 12F | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 233 agents ranked by evidence tier.
JAK2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CEP-33779 | ↓ inhibits | Mechanistic | DGIdb | |
| ITACNOSERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| FILGOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| CEE321 | ↓ inhibits | Mechanistic | DGIdb | |
| MOMELOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GILTERITINIB | ? unclear | Mechanistic | DGIdb | |
| PEMBROLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| NEZULCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| GANDOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| PACRITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| CEP-11981 | ? unclear | Mechanistic | DGIdb | |
| GUSACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| ITACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| ENTRECTINIB | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | 94.0 nM (Kd) | DGIdb |
| TOFACITINIB CITRATE | ↓ inhibits | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 7000.0 nM (Kd) | DGIdb |
| 6-AZAURIDINE | ? unclear | Mechanistic | DGIdb | |
| BOMEDEMSTAT | ? unclear | Mechanistic | DGIdb | |
| AT-9283 | ↓ inhibits | Mechanistic | 1.2 nM (IC50) | DGIdb |
| UPADACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| RUXOLITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 190.0 nM (Kd) | DGIdb |
| AZD1208 | ? unclear | Mechanistic | DGIdb | |
| DECERNOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-1530 | ↓ inhibits | Mechanistic | DGIdb | |
| HG-10-102-01 | ↓ inhibits | Mechanistic | DGIdb | |
| ROVADICITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| JAK3 INHIBITOR II | ↓ inhibits | Mechanistic | DGIdb | |
| IZENCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| EMZELTRECTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| FEDRATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| LESTAURTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| OLAPARIB | ? unclear | Mechanistic | DGIdb | |
| FEDRATINIB HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| JNJ-7706621 | ↓ inhibits | Mechanistic | 220.0 nM (Kd) | DGIdb |
| TOFACITINIB | ↓ inhibits | Mechanistic | 11.0 nM (IC50) | DGIdb |
| DELGOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| BINIMETINIB | ? unclear | Mechanistic | DGIdb | |
| BIIB068 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 307 agents ranked by evidence tier.
MC1R
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AFAMELANOTIDE | ↑ activates | Mechanistic | 0.5 nM (Ki) | DGIdb |
| [125I]NDP-MSH | ↑ activates | Mechanistic | DGIdb | |
| HS024 | ↓ inhibits | Mechanistic | DGIdb | |
| BREMELANOTIDE | ↑ activates | Mechanistic | DGIdb | |
| CORTICOTROPIN | ↑ activates | Mechanistic | DGIdb | |
| MS05 | ↑ activates | Mechanistic | DGIdb | |
| MT-II | ↑ activates | Mechanistic | DGIdb | |
| Α-MSH | ↑ activates | Mechanistic | DGIdb | |
| ASIP [90-132 (L89Y)] | ↓ inhibits | Mechanistic | DGIdb | |
| ISOFLURANE | ? unclear | Mechanistic | DGIdb | |
| DERSIMELAGON | ↑ activates | Mechanistic | DGIdb | |
| SETMELANOTIDE | ↑ activates | Mechanistic | DGIdb | |
| SHU9119 | ↑ activates | Mechanistic | DGIdb | |
| HS014 | ↑ activates | Mechanistic | DGIdb | |
| DESIPRAMINE | ? unclear | Mechanistic | DGIdb | |
| AFAMELANOTIDE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| MODIMELANOTIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL437822 | ↑ activates | Mechanistic | 1330.0 nM (EC50) | ChEMBL |
| CHEMBL24892 | ↑ activates | Mechanistic | 0.4 nM (EC50) | ChEMBL |
| CHEMBL412174 | ↑ activates | Mechanistic | 140.0 nM (EC50) | ChEMBL |
| CHEMBL264337 | ↑ activates | Mechanistic | 480.0 nM (EC50) | ChEMBL |
| CHEMBL439361 | ↑ activates | Mechanistic | 1275.0 nM (EC50) | ChEMBL |
| CHEMBL2371902 | ↑ activates | Mechanistic | 5.0 nM (EC50) | ChEMBL |
| CHEMBL3037885 | ↑ activates | Mechanistic | 0.3 nM (EC50) | ChEMBL |
| CHEMBL410148 | ↑ activates | Mechanistic | 12.0 nM (EC50) | ChEMBL |
| CHEMBL2371880 | ↑ activates | Mechanistic | 735.0 nM (EC50) | ChEMBL |
| CHEMBL415341 | ↓ inhibits | Mechanistic | 5815.0 nM (IC50) | ChEMBL |
| CHEMBL2371903 | ↑ activates | Mechanistic | 3.0 nM (EC50) | ChEMBL |
| CHEMBL2371913 | ↑ activates | Mechanistic | 900.0 nM (EC50) | ChEMBL |
| CHEMBL386871 | ↑ activates | Mechanistic | 480.0 nM (EC50) | ChEMBL |
| CHEMBL384036 | ↓ inhibits | Mechanistic | 14790.0 nM (IC50) | ChEMBL |
| MELATONAN | ↑ activates | Mechanistic | 0.6 nM (EC50) | ChEMBL |
| CHEMBL407754 | ↑ activates | Mechanistic | 370.0 nM (EC50) | ChEMBL |
| CHEMBL2371887 | ↑ activates | Mechanistic | 420.0 nM (EC50) | ChEMBL |
| CHEMBL407825 | ↓ inhibits | Mechanistic | 47.5 nM (Ki) | ChEMBL |
| CHEMBL316259 | ↓ inhibits | Mechanistic | 30.0 nM (Ki) | ChEMBL |
| CHEMBL88630 | ↓ inhibits | Mechanistic | 86.5 nM (Ki) | ChEMBL |
| CHEMBL312998 | ↓ inhibits | Mechanistic | 11.5 nM (Ki) | ChEMBL |
| CHEMBL316038 | ↓ inhibits | Mechanistic | 125.0 nM (Ki) | ChEMBL |
| CHEMBL419307 | ↓ inhibits | Mechanistic | 6.0 nM (Ki) | ChEMBL |
Showing top 40 of 139 agents ranked by evidence tier.
TYK2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| JAK3 INHIBITOR 34 | ↓ inhibits | Mechanistic | DGIdb | |
| SDC-1801 | ↓ inhibits | Mechanistic | DGIdb | |
| TOFACITINIB | ↓ inhibits | Mechanistic | 250.0 nM (Kd) | DGIdb |
| GOLIDOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| TYK2 INHIBITOR 18 [WO2023227946] | ~ modulates | Mechanistic | DGIdb | |
| GDC-0214 | ↓ inhibits | Mechanistic | DGIdb | |
| TAMATINIB | ? unclear | Mechanistic | DGIdb | |
| JAK INHIBITOR 20A | ↓ inhibits | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| PEFICITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| TYD-68 | ? unclear | Mechanistic | DGIdb | |
| BREPOCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| LORPUCITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 25AP [PMID: 37796543] | ↓ inhibits | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 510.0 nM (Kd) | DGIdb |
| FILGOTINIB MALEATE | ↓ inhibits | Mechanistic | DGIdb | |
| DEURUXOLITINIB PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| MOMELOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 13 [PMID: 34333981] | ↓ inhibits | Mechanistic | DGIdb | |
| DEUCRAVACITINIB | ~ modulates | Mechanistic | DGIdb | |
| CADEFRECITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| RUXOLITINIB | ↓ inhibits | Mechanistic | 19.0 nM (IC50) | DGIdb |
| JNJ-7706621 | ? unclear | Mechanistic | 32.0 nM (Kd) | DGIdb |
| BMS-986202 | ↓ inhibits | Mechanistic | DGIdb | |
| FILGOTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 30 [PMID: 37057760] | ↓ inhibits | Mechanistic | DGIdb | |
| SJ988497 | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERLEUKIN-2 | ? unclear | Mechanistic | DGIdb | |
| CERDULATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| EDODEKIN ALFA | ? unclear | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| FEDRATINIB | ↓ inhibits | Mechanistic | 150.0 nM (IC50) | DGIdb |
| UPADACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| SAR-20347 | ↓ inhibits | Mechanistic | DGIdb | |
| ZOTIRACICLIB | ↓ inhibits | Mechanistic | DGIdb | |
| GÖ 6976 | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 13AC [PMID: 33256400] | ↓ inhibits | Mechanistic | DGIdb | |
| TYK2 INHIBITOR 14L | ↓ inhibits | Mechanistic | DGIdb | |
| OCLACITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 223 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ARBUTIN | ↓ inhibits | Mechanistic | 30260.0 nM (IC50) | DGIdb |
| NEORAUFLAVANE | ↓ inhibits | Mechanistic | DGIdb | |
| MEQUINOL | ↓ inhibits | Mechanistic | DGIdb | |
| LUTEOLIN | ? unclear | Mechanistic | 60000.0 nM (IC50) | DGIdb |
| HYDROQUINONE | ? unclear | Mechanistic | 15000.0 nM (IC50) | DGIdb |
| N-PHENYLTHIOUREA | ? unclear | Mechanistic | DGIdb | |
| KOJIC ACID | ? unclear | Mechanistic | 22940.0 nM (IC50) | DGIdb |
| CHRYSIN | ? unclear | Mechanistic | DGIdb | |
| MONOBENZONE | ↓ inhibits | Mechanistic | DGIdb | |
| IMMUNOTHERAPY REGIMEN MKC-1106-MT | ? unclear | Mechanistic | DGIdb | |
| MELANOMA VACCINE | ? unclear | Mechanistic | DGIdb | |
| ALPHA-THUJAPLICIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL430491 | ↓ inhibits | Mechanistic | 780.0 nM (IC50) | ChEMBL |
| CHEMBL98924 | ↓ inhibits | Mechanistic | 390.0 nM (IC50) | ChEMBL |
| CHEMBL98925 | ↓ inhibits | Mechanistic | 330.0 nM (IC50) | ChEMBL |
| CHEMBL321140 | ↓ inhibits | Mechanistic | 4480.0 nM (IC50) | ChEMBL |
| CHEMBL432017 | ↓ inhibits | Mechanistic | 2180.0 nM (IC50) | ChEMBL |
| CHEMBL317947 | ↓ inhibits | Mechanistic | 2130.0 nM (IC50) | ChEMBL |
| CHEMBL317040 | ↓ inhibits | Mechanistic | 240.0 nM (IC50) | ChEMBL |
| CHEMBL95890 | ↓ inhibits | Mechanistic | 6170.0 nM (IC50) | ChEMBL |
| CHEMBL25249 | ↓ inhibits | Mechanistic | 16660.0 nM (IC50) | ChEMBL |
| CHEMBL25640 | ↓ inhibits | Mechanistic | 3030.0 nM (IC50) | ChEMBL |
| CHEMBL26443 | ↓ inhibits | Mechanistic | 23210.0 nM (IC50) | ChEMBL |
| CHEMBL1793857 | ↓ inhibits | Mechanistic | 15350.0 nM (IC50) | ChEMBL |
| CHEMBL24152 | ↓ inhibits | Mechanistic | 60.0 nM (IC50) | ChEMBL |
| CHEMBL1794031 | ↓ inhibits | Mechanistic | 700.0 nM (IC50) | ChEMBL |
| CHEMBL24579 | ↓ inhibits | Mechanistic | 14510.0 nM (IC50) | ChEMBL |
| CHEMBL24765 | ↓ inhibits | Mechanistic | 8000.0 nM (IC50) | ChEMBL |
| CHEMBL25350 | ↓ inhibits | Mechanistic | 2390.0 nM (IC50) | ChEMBL |
| CHEMBL24151 | ↓ inhibits | Mechanistic | 2000.0 nM (IC50) | ChEMBL |
| CHEMBL350966 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CUMINALDEHYDE | ↓ inhibits | Mechanistic | 50000.0 nM (IC50) | ChEMBL |
| CHAMAECIN | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| BRYOAMARIDE | ↓ inhibits | Mechanistic | 85010.0 nM (IC50) | ChEMBL |
| CYCLOORBICOSIDE G | ↓ inhibits | Mechanistic | 54640.0 nM (IC50) | ChEMBL |
| ASKENDOSIDE B | ↓ inhibits | Mechanistic | 13950.0 nM (IC50) | ChEMBL |
| ASKENDOSIDE D | ↓ inhibits | Mechanistic | 48920.0 nM (IC50) | ChEMBL |
| CYCLOSIEVERSIOSIDE | ↓ inhibits | Mechanistic | 92250.0 nM (IC50) | ChEMBL |
| CHEMBL201626 | ↓ inhibits | Mechanistic | 38000.0 nM (IC50) | ChEMBL |
| CHEMBL199975 | ↓ inhibits | Mechanistic | 31700.0 nM (IC50) | ChEMBL |
Showing top 40 of 162 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Vitiligo: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe non-segmental vitiligo.. Vitiligo is a chronic autoimmune skin disorder characteri...
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sid...
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.
The goal of this clinical trial is to learn if adding topical tacrolimus or topical tyrosine to narrowband UVB phototherapy works to treat vitiligo in adults. It will also learn about the safety of both combinations. The main questions it aims to answer are: Which combination (UVB + tacrolimus or UV...
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to inv...
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less...
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-se...
This study is looking at a skin condition called vitiligo. Vitiligo is a skin condition where patches of the skin lose their natural color and become white. This study focuses specifically on vitiligo that affects the face. The treatment being tested is a cream called Anzupgo, which contains an acti...
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
The goal of this clinical trial is to learn if oral mini pulse (OMP) dexamethasone works to treat active vitiligo in children and also learn about the safety of this drug within this age group the main questions it aims to answer are does OMP halt activity in active vitiligo and what medical problem...
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
Agents Found By Disease-Level Search
Searched directly from “Vitiligo” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
45 agents shown (approved or with trial evidence) — 41 not found by the gene-target search above.
Ruxolitinib creamNOT in gene-target list
PF-06651600NOT in gene-target list
NB-UVB phototherapyNOT in gene-target list
Ritlecitinib
Upadacitinib
narrow-band UVB phototherapyNOT in gene-target list
Topical tacrolimus 0.1% ointmentNOT in gene-target list
SHR0302Base gelNOT in gene-target list
ApremilastNOT in gene-target list
derma penNOT in gene-target list
Ruxolitinib 1.5% Cream BIDNOT in gene-target list
Needling + NBUVBNOT in gene-target list
Deucravacitinib
PF06700841NOT in gene-target list
LITFULONOT in gene-target list
LITFULO and UVBNOT in gene-target list
VITICELLNOT in gene-target list
Ritlecitinib 100 mgNOT in gene-target list
Coenzyme Q10NOT in gene-target list
Vitamin CNOT in gene-target list
AzathioprineNOT in gene-target list
Tofacitinib
Ginkgo bilobaNOT in gene-target list
Ruxolitinib Topical CreamNOT in gene-target list
Grafting with epidermal cellsNOT in gene-target list
UVB treatmentNOT in gene-target list
Gingival depigmentationNOT in gene-target list
oral mini pulseNOT in gene-target list
Topical creamNOT in gene-target list
targeted phototherapyNOT in gene-target list
Autologous Nanofat InjectionNOT in gene-target list
dibotatug (DR-01)NOT in gene-target list
1.5% Ruxolitinib Phosphate Cream (Opzelura)NOT in gene-target list
Corticosteroid TherapyNOT in gene-target list
Ruxolitinib TopicalNOT in gene-target list
MethotrexateNOT in gene-target list
EtanerceptNOT in gene-target list
ReCellNOT in gene-target list
diphenylcyclopropenone (DPCP)NOT in gene-target list
Drug: CGB-600 gel, experimental drugNOT in gene-target list
Dexamethasone (0.1 mg/kg)NOT in gene-target list
Ruxolitinib 1.5% creamNOT in gene-target list
FB102NOT in gene-target list
MH004 1.0% OintmentNOT in gene-target list
Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinetNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.